Floatz logo

DABIGATRAN ETEXILATE

Intracranial Hemorrhage

University Hospital, EssenSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Intracranial Hemorrhage cohort.

Asset / SponsorPhaseRating
Idarucizumab 2.5 Gm/ Intravenous [Praxbind]
University Hospital, Essen
D

Same molecule, other indications

DABIGATRAN ETEXILATE is also rated in:

atrial fibrillationDormant
BB
Indicative ·
67 / 100
View asset →
type 2 diabetes mellitusDormant
BB
Indicative ·
65 / 100
View asset →
chronic kidney diseaseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →